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 Moore, Anna Billings. M.S. The University of Memphis. May/2011. Vitamin 
D Supplementation in Persons with Parkinson’s Disease. Major Professor: Dr. 
Brian K. Schilling. 
 Individuals with Parkinson’s disease (PD) have a higher incidence of 
osteoporosis and hypovitaminosis D. Vitamin D supplementation has not been 
widely evaluated in people with PD for bone and muscular health. This 
investigation examined the effects of vitamin D supplementation over 12 weeks 
(treatment n=5; control n=2) in PD.  Subjects performed one repetition maximum 
for leg and chest press, six-minute walk, timed up and go, and quality of life 
questionnaires. Blood samples were analyzed for Vitamin D levels and markers 
of bone turnover. Dual x-ray absorptiometry scans were performed to determine 
body composition and bone quality data.  Significant improvements (p<0.05) 
were found in relative strength for one repetition maximum chest press, as well 
as fat mass for the treatment group when compared to controls, indicating a 
positive effect of vitamin D supplementation.  No other significant differences 
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 Parkinson's Disease (PD) is a central nervous system disorder generally 
diagnosed in older adult populations (60+years of age). PD is chronic and 
progressive, originating in the substantia nigra region located deep within the 
brain. Dopamenergic neurons, which produce and use the neurotransmitter 
dopamine are located within the substantia nigra, and progressively die. This 
chain of events leads to reduced levels of dopamine in the brain, which causes 
several disabling signs and symptoms. These signs and symptoms include 
bradykinesia (slowness of movement), reduced muscular strength and function, 
postural instability, “masked “ facial expression, and resting tremor, all of which 
negatively affect the patient's quality of life and ability to perform many activities 
of daily living [33]. Drug therapy in PD which may include Levodopa, dopamine 
receptor agonists, and monoamine oxidase inhibitors, can alleviate some of 
these symptoms, but can leave the patient feeling anxious, lethargic, dizzy, and 
cause psychiatric disturbances, such as vivid dreams, delusions, hallucinations, 
and mania [33]. Thus, other potential therapies warrant investigation. 
 Vitamin D is important for bone health and skeletal muscle function [8]. 
Much research on Vitamin D supplementation has been conducted in healthy 
populations [17,18] and although previous studies have investigated Vitamin D 
levels in those with PD [11, 22, 23, 24, 25, 26, 27, 28], more information is 
needed to better understand the effects of Vitamin D supplementation in this 
population. Previous research shows that persons with PD have a high 
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prevalence for Vitamin D insufficiencies and deficiencies, but to date only one 
study has examined Vitamin D supplementation in PD patients [28].  In this 
particular study, subjects took 1µg (40 IU) of 1, 25 (OH)2D3 daily over a period of 
18 months. The findings of this study are important because they demonstrate 
that vitamin D supplementation can slow the reduction of BMD, and reduce the 
risk of fracture in persons with PD. However, this investigation did not examine 
the effect the treatment had on muscular strength and functional mobility [28], 
which is important in the context of the findings of Ceglia  and Deluca, showing a 
relationship between vitamin D and muscle function in neurologically normal 
adults [8, 9]. The present study investigated the effects of a higher dose of 
vitamin D3 on indices of muscular strength and functional mobility, as well as 
BMD and blood markers of bone turnover, in persons with PD. 
METHOD 
SUBJECTS 
 Seven men and one woman between the ages of 55 and 80 were 
recruited to participate in this study. Subjects had a previous diagnosis of 
idiopathic PD by a board-certified neurologist. Individuals who had orthostatic 
hypotension, dementia, and other co-morbidities such as stroke, and severe 
degenerative osteoarthritis were excluded, as well as the exclusion of those 
individuals with other known causes of Parkinsonism such as vascular PD, 
progressive supranuclear palsy, and multiple symptom atrophy. Those with 
hypersensitivity to vitamin D or those that are supplementing with vitamin D 
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above 800 IU daily were also excluded. A board-certified neurologist performed a 
Unified PD Rating Scale (UPDRS) within one month prior to the subject’s initial 
lab visit [29, 30].  
PROCEDURES 
       Subjects were required to come to the laboratory on three occasions. Upon 
providing written informed consent as approved by the university institutional 
review board for human subjects research, subjects completed a health history, 
medication and supplement usage questionnaire, and fitness activity 
questionnaire for screening purposes. Subjects then completed the Fatigue 
Severity Scale (FSS), a questionnaire commonly used with multiple sclerosis and 
other conditions, designed to distinguish fatigue from clinical depression [29, 30]. 
They also completed the PD Questionnaire-39 (PDQ- 39), the most widely used 
specific measure of health status in persons with PD, and the Beck Depression 
Inventory (BDI) often used in this population to quantify emotional state [29, 30]. 
Finally the subjects answered the ABC Activities-Specific Balance Confidence 
(ABC) questionnaire. This is a measure of subjects’ feeling of self-confidence 
when performing activities of daily living [29, 30]. Practice of the performance 
tests immediately followed paperwork during this initial lab visit.  
One repetition maximum (1 RM) for a leg press and chest press on 
machines (Hammer Strength, Schiller Park, IL) was determined following a 
standard protocol [29, 30]. The 1RM values were adjusted for body mass 
according to Schilling et al. [29, 30], and are thus expressed as relative values. 
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Practice sessions for a 6-minute walk test (6MW) and the Timed Up and Go 
(TUG) test were performed [29, 30]. When performing the TUG, subjects were 
instructed to rise from a seated position, walk three meters, turn, and walk back 
to the chair, and return to a seated position. Subjects were allowed to use any 
assistive devices normally used during their usual activity. Timing began at liftoff 
from the chair and ended when the patient touched back down upon return to the 
chair. When performing the 6MW, subjects stood in a 100-foot walkway and were 
instructed to walk laps back and forth as fast as possible without running, 
following a 30-meter path. Subjects were allowed to rest if needed and were 
permitted to use any walking aids such as canes or walkers that they may have 
used in normal walking activities. The object was to cover as much distance as 
possible in six minutes [29, 30]. 
 During the second laboratory visit, the subjects reported to the lab in a 12-
hour fasted state. Venous blood samples were taken from subjects’ antecubital 
vein via needle and collection tube, by a trained phlebotomist. Samples were 
collected before and after the intervention period, while subjects were in a 12 
hour fasted and rested state. Blood was collected in tubes with no additive and 
was allowed to clot for 30 min at room temperature and then centrifuged at 1500 
rpm for 15 min at 4°C. The serum was then stored in multiple aliquots at -70°C 
until analyzed. Samples were analyzed for 1,25-dihydroxyvitamin D3 (Product 
No: CDN-E0877), Human Cross Linked N-Telopeptide of Type I Collagen 
(Product No: CDN-E0362), and Human Bone Alkaline Phosphatase (Product No: 
CDN-E0823) using enzyme linked immunosorbent assay (ELISA) procedures 
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(Creative Diagnostics: Shirley, NY). All assays were performed in triplicate on 
first thaw.   
The subjects then had a dual x-ray absorptiometry (DXA) scan performed 
(Holgic ODR 4500,Bedford, MA) to measure whole body composition including 
fat mass (FM), lean mass (LM), and total body mass (TBM), as well as skeletal 
variables including bone mineral density (BMD), bone mineral content (BMC), 
and area. Subjects were allowed to bring a small snack for consuming after the 
blood draw. After a standardized five-minute warm up, subjects then performed 
the TUG and 6MW.  
Subjects were given Vitamin D supplements or identical appearing and 
tasting placebo and instructed to take four tablets daily for a period of 12 weeks. 
The chewable tablets consisted of 1000 IU Vitamin D per tablet (NOW foods, 
Bloomingdale, IL), and subjects were instructed to ingest these with their largest 
meal of the day. Before leaving the lab on this second visit, subjects were also be 
given instructions for preparation for the final laboratory visit. Weekly phone calls 
were made to subjects to help promote compliance. In the instances subjects did 
not answer, when possible a reminder voicemail message was left. As needed, 
subjects visited the testing site again for another bottle of tablets when they were 
almost gone. In the event subjects were unable to get to the testing site, 
researchers took the appropriate bottles to the subject’s location.  
After the 12-week intervention, subjects reported for the final laboratory 
visit in a fasted state. Blood draws, DXA scan and physical tests performed in the 
6 
 
final laboratory visit were identical to those performed in the second visit. 
Subjects again filled out a FSS, PDQ-39, BDI as well as the ABC questionnaire. 
 STATISTICS 
  Data are presented as mean±SD. A 2 x 2 RMANOVA was run for (group) 
x (time) to compare the strength and function measures, body composition, blood 
markers and bone health measures of the supplement and placebo groups 
before and after the 12-week treatment. Tukey post-hoc tests were used in cases 
of significant interaction to examine within-group changes over time. 
RESULTS 
 
Eight subjects were originally recruited for this study, and one dropped out 
due to a severe worsening of PD symptoms.  This subject’s withdrawal left seven 
participants.  Two post-tests were incomplete. These included one leg press 
1RM, because the subject had sustained a back injury unrelated to the study, 
and one chest press 1RM because the subject had a flare up of an existing 
shoulder injury. Because many of the values were below the detectable limit for 
NTx and 1,25 dihydroxyvitamin D, only results for BALP were obtained. 
Descriptive information and pre and post-intervention data are presented in 
Tables 1 and 2, respectively. Significant interactions (p<0.05) were found for two 
variables: FM (p=.02) and RelCP1RM (p=.007). Tukey post-hoc tests revealed 
both a significant increase (p<0.05) in RelCP1RM in the treatment group, and a 
significant decrease (p<0.05) in the control group over time. Tukey post-hoc tests 
7 
 
also revealed a significant increase (p<0.05) in FM in the control group over time. 
There were no significant interactions (p>0.05) for BALP (p=0.83), LBM 
(p=.687),BMC (p=.694), area (p=.679) BMD (p=.383), RelLP 1 RM (p=.523), 
6MW (p=.195), TUG (p=.109), FSS (p=.685), BDI (p=.368), PDQ-39 (p=.173), or 
ABC (p=.131) for either group after at least 84 days of treatment. All time and 
condition effects were non-significant (p>0.05). 
 
DISCUSSION 
Muscle function and vitamin D supplementation has not been studied in 
PD. Although the sample size for this investigation was small, there are some 
noteworthy findings for body composition and muscle strength after 12-weeks of 
4000 IU/d of vitamin D versus a placebo. Although this dose is higher than the 
current recommend daily value of 400 IU, Vitamin D toxicity is not likely to occur 
at the dosage used in the present study [12]. No adverse events were reported 
by any subjects during or after intervention.  
Bone and Body Composition 
  There were no significant changes in TBM or LBM, which is not 
uncommon in a study of this short duration. Previous research demonstrates a 
positive relationship with serum vitamin D levels and type II muscle fiber diameter 
[8]. Conversely, low levels of vitamin D are correlated with higher amounts of 
intramuscular fat, as well as type II muscle fiber atrophy [8]. This relationship 
between serum vitamin D levels and body composition is important, because in 
addition to the expected sarcopenia that occurs with advanced age, type II 
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muscle fiber atrophy could be dangerous, especially to people with PD, because 
those are the first fibers recruited in the event of a fall. We did find a significant 
interaction (p=0.021) in FM between groups over time. Tukey post-hoc tests 
revealed a significant increase (p<0.05) in FM in the placebo group (pretest 
mean 42.6±46.4kg, post test mean 44.0±.47.0kg) As previously mentioned, low 
vitamin D levels are correlated with higher amounts of intramuscular fat. The 
findings in this study are interesting because they suggest that vitamin D 
supplementation in people with PD may play a role in attenuating that increase in 
FM.  
There were also no significant changes in BMD, BMC, or area. As 
previously stated, it is not uncommon for a study of this short duration not to 
show changes in bone density, because of the rate of typical bone remodeling 
[1]. However, the fact that there was no loss in bone density is beneficial, as 
there is a higher incidence of osteoporosis in people with PD [1]. According to 
Sato et al, BMD in individuals with PD is positively correlated with vitamin D 
status. Furthermore, vitamin D supplementation via sunlight exposure or oral 
intake may attenuate loss of BMD in people with PD [23, 28]. 
PERFORMANCE 
There was a significant interaction (p=0.007) for RelCP1RM.  The 
treatment group significantly (p<0.05) increased from a mean score of 0.9 ±.0.2, 
to a mean score of 1.0±0.3 post-intervention. This was an 11% increase in 
strength. The control group also had a significant (p<0.05) decrease in  
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RelCP1RM. As stated by Schilling et al. [29, 30], muscular strength relative to 
body mass is lower in PD and this weakness may be related to symptoms of PD 
such as muscular atrophy, postural instability and bradykinesia. Those 
investigators [29, 30] stressed the need to develop new interventions to alleviate 
these impairments. This finding suggests that vitamin D supplementation in PD 
may not only attenuate the disease-related muscular atrophy, but it may also 
increase relative strength, which is necessary for quality of life (QoL) and 
activities of daily living.  Since 1RM appears to be stable in the population over 
time [30], it is possible that the changes in 1RM are related to use of the 
supplementation. Of course, other factors not measured in the current study such 
as dietary intake and motivation to perform the chosen exercises on the test days 
could have been responsible for our findings. RelLP1RM for both groups had no 
significant change, but the control group decreased from mean 3.0±1.3 pre-
intervention, to 2.8±1.8 post intervention, a 6.7% reduction in relative strength. 
The treatment group had no change in RelLP1RM, with a mean of 3.2±0.9 pre-
intervention, and a mean of 3.2±0.8 post-intervention. It is noteworthy that a 
significant interaction occurred for the upper –body strength test, but not for the 
lower-body strength test. It is possible that although subjects had the opportunity 
to rest, leg fatigue may have played a role. Subjects did walk from the parking 
garage into the testing facility, a distance that proved challenging for some 
subjects. Due to construction occurring at the time, subjects were also forced to 
walk across some unstable surfaces.  
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Functional mobility tests showed no statistically significant change in 
either group, but some practical changes were noted. The treatment group 
improved 6MW distance from 398.1±132.3m initially, to a post-intervention mean 
468.3±106.1m, a 17.6% increase, and improved TUG times, initial mean 11.1± 
4.5 s, post-intervention mean 9.3±4.0s, a 16% improvement. The control group 
decreased performance in the 6MW, initial mean 472.3±285.6m, to a post-
intervention mean 448.1± 397.4m, and TUG tests, initial mean 12.6±9.3s, to 
post-intervention mean 13.0±9.2s. These were 5%, and 3% reductions in 
performance, respectively. These data are also important for quality of life of 
people with PD. Those with PD are generally older and have older spouses who 
often take on the role of care-giver. Therefore, the length of time the patient can 
stay independent for activities of daily living such as rising from a chair, getting 
into and out of vehicles and walking around the house, or from the vehicle into a 
store, factors not only into the QoL, but also the emotional state and cost of 
having PD. 
SELF-REPORTED QUALITY of LIFE 
There were no significant changes in any of the QoL questionnaires 
administered in this investigation. Mean scores for both groups on the FSS were 
well above the threshold for normal fatigue, which is a score of 36, indicating that 
both groups did suffer from excessive fatigue due to the effects of PD, pre-and 
post intervention.  The group treated with vitamin D had no change in perceived 
fatigue (initial mean 42.4±12.0, post-test mean 42.4±7.4), while the control group 
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(initial mean 58.0±2.8, post-test mean 61.5± 2.1) had a 6% decline. Although 
there was an increase in BDI scores for the treatment group (initial mean 
8.2±4.5, post-intervention mean 8.8±7.6), of 7.3%, the mean value still fell within 
the range for mild depression.  BDI scores for the control group actually fell 
(initial mean 20.2±8.5, post-intervention mean 18.5±13.4) by 7.5%, however this 
group was classified as moderately depressed pre-intervention and remained 
within that range.  ABC scores for both groups demonstrated a moderate level of 
physical functioning pre-intervention. The treatment group had a slight decrease 
in function from a pre-intervention mean of 71.4±23.1, to post-intervention mean 
of 69.5±27.1, a 2.6% decline, remaining at a moderate level, while the control 
group actually increased (initial mean 64.5±27.6, post-intervention mean 
87.8±4.9) 26.8% suggesting a higher level of physical function. This is likely due 
to the fact that one subject was unable to write or speak well the day of post-
testing, and his wife assisted him in filling out the survey, thus interjecting 
potential error.  PDQ-39 scores for both groups dropped 10.5% by post-
intervention.   
LIMITATIONS AND FUTURE DIRECTIONS 
Several important things must be noted.  Firstly, this study was done with 
a very small sample size—primarily due to problems with subject recruitment, 
which were influenced by the widespread use of vitamin D within PD patients. 
Many potential subjects were found to be already supplementing above the pre-
determined cut-off for this study of 800IU/day. A future follow-up study should 
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include those individuals already supplementing and the dosage limit set in the 
present study should be increased. Vitamin D toxicity is known to occur at a 
dosage of 50,000 IU/d for several months; however evidence supports the safety 
of an intake at 10,000 IU/d [12].  
Our findings included a significant interaction between groups over time 
for FM (p<0.021), with post-hoc tests revealing that the control group had a 
significant increase (p<0.05). While this interaction could be due to vitamin D 
supplementation, we did not have dietary information for the intervention period. 
It is possible that the subjects changed their caloric intake or other dietary habits. 
Subjects were instructed to maintain current level of physical activity, however 
inclement weather that occurred during the intervention period may have affected 
group exercise class attendance by the subjects. Change in exercise habits 
could potentially play a role in any changes in body composition. 
A final important note is that many PD patients report fluctuations in their 
symptoms [33]. As previously mentioned, one subject in particular was 
experiencing aphasia on the day of post-testing, thus; he had difficulty 
communicating answers to surveys. If he was in fact feeling “off” during testing 
for other performance measures, potential error plays a role in the data we 






 The findings of this study suggest vitamin D supplementation in 
people with PD may increase relative strength, as well as play a role in body 
composition. These findings are very important in this population because 
reduced muscular strength, especially in those with advanced PD, is an inherent 
characteristic of the disease itself that becomes more severe as the disease 
progresses [29, 30, 33]. This reduced muscular strength could potentially affect 
QoL, as many PD patients rely on assistance for activities of daily living. Because 
there is no cure for this disease, it is important to investigate other therapies that 












Table 1   Descriptive Subject Data (mean±SD) 
Variable Treatment Group, 
male=4, female=1 
Control Group, male=2, 
female=0 
Hohen and Yahr (on) Stage1.5, n=1; Stage 2, 
n=3; Stage 2.5, n=1 
Stage 2, n=1; Stage 3, 
n=1 
UPDRS 13.8±6.1 18.5±3.5 
TBM (kg) 73.3 ± 5.7 98.0 ± 37.9 
Age (y) 66.4 ± 8.9 66.5 ± 12.5 














Table 2     Pre and Post-intervention Data (mean±SD).                               
 Treatment Group (n=5) Control Group (n=2) 
Measure Pre Post Pre Post 
LBM 
(kg) 
51.5±6.2 51.6±5.4 55.4±8.4 55.0±10.7 
FM(kg)* 21.8±5.5 20.8±5.9 42.6±46.4 44.0±47.0~ 
TBM 
(kg) 
73.3±5.7 72.4±6.4 98.0±37.9 99.0±36.3 
BMC (g) 2506.9±248.3 2492.6±240.8 2962.7±501.7 2966.8±595.7 
Area 
(cm2) 
2121.8±93.0 2123.8±82.5 2235.3±160.9 2209.4±285.8 
BMD 
(g/cm2 ) 
1.2±07 1.2±0.1 1.3±0.1 1.3±0.1 
RelCP 1 
RM* 
0.91±0.2 0.95±0.3~ 0.94±0.5 0.85±0.5^ 
RelLP 
1RM 
3.2±0.9 3.2±0.8 3.0±1.3 2.8±1.8 
6MW 
(m) 
398.1±132.3 468.3±106.1 472.3±285.6 448.1±397.4 
TUG (s) 11.1±4.5 9.3±4.0 12.6±9.3 13.0±9.2 
FSS 42.4±12.0 42.4±7.4 58.0±2.8 61.5±2.1 
BDI 8.2±4.5  8.8±7.6 20.0±8.5 18.5±13.4 
PDQ-39 83.6±31.2 74.8±21.8  118.5±24.7 106.0±29.7 
ABC 71.4±23.1  69.5±27.1 64.5±27.6 87.8±4.9 
*Significant interaction noted(p<0.05).  ~ indicates significant gain over time.(p<0.05) ^ indicates 
significant decrease over time.(p<0.05)LBM = lean body mass; FM= fat mass; TBM= total body 
mass; BMC= bone-mineral composition; BMD= bone-mineral density; CP 1 RM = chest press 
one-repetition maximum;, RELCP1RM= relative chest press one-repetition maximum; LP1RMkg= 
leg press one-repetition maximum; RELLP1RM= relative leg press one repetition maximum; 
6MW= six-minute walk; TUG= timed up and go; FSS= fatigue severity scale; BDI= Beck 
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EXTENDED LITERATURE REVIEW 
INTRODUCTION 
Parkinson's Disease (PD) is a central nervous system disorder generally 
diagnosed in older adult populations (60+years of age). PD is a chronic, 
progressive neurodegenerative disease that originates in the substantia nigra 
region located deep within the brain. Dopamenergic neurons, which produce and 
use the neurotransmitter dopamine are located within the substantia nigra, and 
progressively die off in persons with PD. This chain of events leads to reduced 
levels of dopamine in the brain, which causes several disabling signs and 
symptoms. These signs and symptoms include bradykinesia (slowness of 
movement), reduced muscular strength and function, postural instability, 
“masked “ facial expression, and resting tremor, which negatively affect the 
patient's quality of life and ability to perform many activities of daily living. 
Because PD is progressive in nature, individuals with the disease will have 
greater difficulty functioning in their daily lives as the disease becomes more 
advanced. Facial expressions, such as smiling and blinking, as well as activities 
that keep patients independent such as walking, speaking, and writing become 
more difficult. Patients may lose the ability to perform activities of daily living, 
such as cooking and performing self-care and hygiene tasks. The muscular 
system is also affected as the disease progresses. Muscle tone may change, 
causing dystonia (muscle spasms), and rigidity of the muscles increases. These 
muscular changes are often associated with greater amounts of pain. Drug 
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therapy for persons with Parkinson’s disease, which may include Levodopa 
therapy, dopamine receptor agonists, and MAO inhibitors may leave the patient 
feeling anxious, lethargic, dizzy, swollen, and the patient may have psychiatric 
disturbances, such as vivid dreams, delusions, hallucinations, and mania [33]. 
VITAMIN D 
Vitamin D is an important vitamin for bone health and skeletal muscle 
function. Humans can take in Vitamin D in two ways. Dietary Vitamin D2 or D3 is 
taken in through fortified foods such as milk, cereal, and orange juice, or several 
different kinds of fish oils. Ergocalciferol (Vitamin D2 supplement) and 1,25 
dihydroxyvitamin D, which is the activated form of Vitamin D found in the blood, 
are available with a prescription, and D3 supplements are available over the 
counter. When Vitamin D is taken in orally through D3, it takes the form of over 
33 different metabolites. Many of the metabolites of Vitamin D are dissolved too 
quickly to show up on blood test results, but metabolites 24 and 25, which are 
actually known as hormones, stay in the serum longer. Therefore, when 
measuring Vitamin D levels in the blood, investigators actually measure the 25th 
metabolite of D3, which is known as 25 OH-D [9]. The second way humans take 
in Vitamin D is through 7- dehydrocholesterol in the skin, which is converted to 
pre-vitamin D3 after exposure to ultraviolet B radiation. When sunscreen is worn 
outside, the product blocks the UVB rays necessary for the body to perform the 
conversion [8].  
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 The prevalence of Vitamin D deficiency increases with older populations, 
including neurologically normal older adults (NNOA). A 2009 investigation by 
Bolland, et al, concluded that Vitamin D deficiency was more common in older, 
frail women. The researchers used subjects that were community dwelling 
women with a mean age of 74 years. This was a 5-year trial with 25-OH-D levels 
measured at baseline. Many other health parameters were measured, including 
skeletal bone mineral density, frequency of fractures, falls, and grip strength; as 
well as non-skeletal parameters such as frequency of cancer, death, myocardial 
infarction, cardiac failure, stroke, blood pressure changes, obesity, and blood 
glucose measures. Researchers found that 50% of the women who had a 
Vitamin D deficiency, defined as 25-OH-D concentration less than 50 nmol/L, 
were significantly older, heavier and less physically active than those women 
without Vitamin D deficiency [5]. 
 Reduced levels of vitamin D in older populations were found in a recent 
study of postmenopausal women living in Brazil with no other known causes of 
osteoporosis [3]. Subjects were divided into groups according to age; group 1 
consisted of subjects aged 51-65 years, and group 2 consisted of those subjects 
aged 66-84 years. Serum 25 (OH) D was analyzed for all subjects. Investigators 
found that levels of vitamin D were lower in older subjects. In women age 51-59, 
the prevalence of vitamin D was 30%, in those 60-69 years of age 32.5%, in 
those aged 70-79 years 54.5%, and in those patients over 80 years of age, 
prevalence of vitamin D deficiency was 83% [3]. 
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Vitamin D concentrations and risk for hip fractures were studied in a 
prospective cohort study called the Women’s Health Initiative Observational 
study (Cauley et al. 2008). Baseline clinical measures were taken after dividing 
the clinical centers from which the subjects were associated into three different 
geographic latitude regions. Fasting blood draw was taken, and physical abilities 
and activities were measured through self-report surveys. Investigators found 
that case participants had lower levels of Vitamin D than controls as well as 
higher blood markers of bone resorption (Cauley, et al, 2008). Furthermore, 
Looker et al reported that postmenopausal women with insufficient levels of 
vitamin D vitamin remained insufficient across annual seasonal changes, and 
various latitudes [17]. 
 
VITAMIN D AND PARKINSON’S DISEASE  
       Previous research shows that persons with PD have a high prevalence for 
Vitamin D insufficiencies and deficiencies. A 2008 study examined 300 
individuals from the Clinical Research in Neurology database for a 3-cohort study 
(100 each of patients with Parkinson’s Disease, Alzheimer’s, and a control 
group). A simple blood test was used to determine serum 25 OH-D levels. The 
findings showed that 55% of the subjects with PD were insufficient in Vitamin D 
levels, when compared to 33% of the subjects from the control group. This 
difference of Vitamin D insufficiency was significantly higher in the group of 
subject with PD than in either the group of subjects with Alzheimer’s disease to 
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the control group. In this study, insufficiency was defined as 25(OH) D 
concentration of 30ng/mL or less and Vitamin D deficiency as a 25 (OH) D 
concentration of less than 25 ng/mL [11]. 
A 2006 study investigated 82 subjects over the age of 65 with PD. 68 age 
and BMI matched healthy persons were used for controls. The researchers 
surveyed the patients for history of falling, as well as fractures. DXA was used to 
determine BMD, and blood serum levels of calcium, Vitamin D, and BALP were 
gathered, as well as urinary levels of NTx. Results showed that the subjects with 
PD had lower levels of serum Vitamin D than did the healthy age matched 
controls [31]. 
Vitamin D supplementation has also been investigated in persons with PD 
[28]. They examined the effects of 18 months of vitamin D3 supplementation on 
bone health and the risk of fracture in this population. Subjects were older 
individuals, over the age of 65 who had PD. BMD was measured at the second 
metacarpal using computed x-ray densiometer before the treatment began, and 
again at 18 months. Subjects were divided into two groups, placebo group (n=43) 
and a treatment group (n=43). The treatment group took 1 µg of D3 daily for a 
period of 18 months. Investigators found that the treatment group demonstrated 
17.5% less fractures over the 18 month period than did the placebo group. 
Furthermore, BMD decreased 6.7% in the placebo group, as opposed to a BMD 
reduction of less than two percent in the treatment group. Investigators 
concluded that D3 supplementation depresses fracture rate, and attenuates loss 
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of BMD in patients with PD [28].  A follow-up study investigated BMD status in 
people with PD as it relates to sunlight exposure. Participants were ambulatory 
people with PD who were randomly assigned to either a sunlight exposure group, 
or a usual lifestyle control group. Participants in the sunlight exposure group 
were instructed to spend fifteen minutes per day outside in the sunlight during 
clear conditions. The usual lifestyle group was instructed to maintain lifestyle as 
usual, whether or not it was homebound. BMD status was assessed using 
metacarpal densitometry at the left hand before and after the two-year period. 
BMD in the sunlight-exposed group increased 0.2%, and decreased 0.3% in the 
usual lifestyle group. The difference between these two groups was statistically 
significant. Vitamin D levels increased in the sunlight-exposed group and 
decreased in the usual lifestyle group, and BMD was positively correlated with 
vitamin D status. There were 73% fewer hip fractures due to falls in the exposed 
group as compared to the usual-lifestyle group. Investigators also noted that 
muscular strength at the hip of the sunlight-exposed group was greater after two 
years, and less in the usual-lifestyle group. Researchers concluded that elderly 
people with PD, and low levels of serum vitamin D are at risk for hip fractures 
due to falls, and that sunlight exposure my be an effective way to increase BMD 






PARKINSON’S DISEASE AND BONE HEALTH 
A 2008 study examined bone health of 82 persons with PD. Patients were 
excluded if they had any other known causes of Vitamin D deficiency, or 
osteoporosis, or systemic inflammation so as to analyze the true effect of PD on 
bone health. Researchers used DXA to measure Bone Mineral Density (BMD), 
as well as biochemical measures from fasting serum samples to investigate 
levels of 25 OHD, and (BALP), which is a bone health biomarker. X-RAY 
radiography was used to assess vertebral compression fractures (VCF’s), which 
are common among persons with osteoporosis. This study also examined 
several physical performance measures in persons with PD. The 6-minute walk 
test (6MW), timed  up and go test (TUG), grip strength measures, and activities 
of daily living (ADLs) were assessed. The biochemical measures showed 
significantly lower levels of serum 25-OHD in those subjects with PD as opposed 
to the control group. The group of subjects with PD had lower BMD levels than 
age and sex-matched subjects without PD. The BALP assessments showed that 
bone turnover is increased in patients with PD, resulting in these patients being 
more likely to have a lower BMD measure, and increased risk of fracture as 
compared to the control group. Furthermore, the findings of this study showed 
that persons with PD demonstrated reduced physical and mental performance, 
which could lead to even lower levels of serum Vitamin D and lower BMD [1]. 
A 2009 investigation examined bone health in persons who had been 
diagnosed with PD at least one year prior. DXA for lumbar bone mineral density 
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was performed, as well as measures of muscle function and trunk rigidity. 
Results indicated that lumbar bone mineral density was well below desired levels 
in persons with PD. In fact, 21 percent of the subjects with PD had osteoporosis 
and 37 percent had osteopenia. Furthermore, BMD was significantly positively 
correlated with trunk strength [20]. In a follow up study, the same investigator 
examined muscular strength and function as well as BMD in women with PD, and 
found that 44 percent of the subjects had either osteopenia or osteoporosis. 
Subjects with PD also demonstrated significantly lower distances for the 6-minute 
walk test, slower walking speed, and higher number of falls. The researcher 
concluded that leg muscle strength is independently associated with bone 
mineral density in women with PD (Pak, 2009). 
A recent study investigated bone health in people with PD over a five-year 
period. Post-menopausal women with typical PD were recruited to participate in 
this study. Investigators monitored vertebral fracture incidence by radiography 
every year of the five-year study, as well as BMD. Vitamin D status and markers 
of calcium metabolism were also noted before and after the five-year period for 
both the stooped posture and non-stooped posture group. BMD and T-score 
were significantly lower in the stooped-posture group than in the non-stooped 
posture group at the end of the study. Investigators also noted that although both 
groups had a significant increase in vertebral fracture incidence, the stooped-
posture group was significantly higher than the non-stooped posture group. In 
both groups, serum calcium, and vitamin D decreased significantly over the five-
year period, however both serum markers were significantly lower in the stooped-
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posture group than in the non-stooped posture group. Researchers concluded 
that stooped-posture in people with PD may be caused by vertebral fractures due 
to low levels of vitamin D, and suggest that supplementation may be beneficial 
[24].  
 
VITAMIN D and BONE  
Bone remodeling is an important part of skeletal health. Normal bone 
metabolism function is affected without the presence of activated vitamin D, 
because the minerals calcium and phosphorous are not absorbed as easily. 
Studies show that only 10 percent of the amount of calcium, and 60 percent of 
the amount of phosphorous are absorbed when compared to normal bone 
metabolism in the presence of activated Vitamin D [8]. The role of Vitamin D, as it 
is metabolized into an active hormone form in vivo, is to stimulate a chain of 
events that will mobilize calcium from bone for mineral resorption. This process is 
especially important when environmental calcium is not available from dietary 
sources. Vitamin D deficiency can lead to osteomalacia / osteoporosis in adults 
and rickets in malnourished children [9]. 
Lower 25 (OH)D levels are correlated with lower bone mineral density 
(BMD). The aforementioned study examined Vitamin D levels in postmenopausal 
women who had osteoporosis. The 96 women who participated in this 
investigation were divided in to two groups, the first being subjects that were 51-
65 years in age, and a second group of women 66-84 years of age. Bone mineral 
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density was measured using dual-energy x-ray absorptiometry (DXA) at both the 
lumbar spine and neck of the femur. In the younger age group, subjects with 
serum 25-OH D levels below 50 nmol/L showed lower BMD at the femoral neck 
than those with higher vitamin D levels [3]. Similar data were found for 
osteoporotic women ages 50-85. This particular study found that women with 
hypovitaminosis D were at a greater risk of osteoporotic fracture than those 
women who were not deficient in vitamin D. Deficiency in this study was defined 
as vitamin D levels of 20 ng/mL or less [2]. 
 Supplementation with vitamin D may attenuate normal BMD loss. A study 
looked at middle aged women, defined as aged 33 years to 55 years, who were 
osteopenic, menstruated regularly, and of normal body weight [18]. Subjects 
were divided into three groups. Group one consisted of middle aged women who 
had normal BMD, and were treated with a daily placebo, Group two consisted of 
subjects who had osteopenia, and were treated with a daily supplement of 
calcium in combination with Vitamin D, and Group three consisted subjects who 
had osteopenia, and took a supplement of calcium, vitamin D and a vitamin B6 
combination. Supplementation was daily and lasted for one year. DXA was used 
to determine BMD at the lumbar spine and femoral neck, while anthropometric 
data were collected including weight, height, and circumference measurements. 
Blood was drawn and bone-specific alkaline phosphatase (BALP), which is a 
biomarker indicating bone remodeling is occurring, and 25(OH) D were analyzed. 
All women were sufficient in 25(OH) D even though self-reported dietary intake of 
the vitamin was low. After one year, BMD decreased, although not significantly, 
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in Group 2 at 5 specific sites, the treatment group of Ca/D alone. No significant 
BMD loss was seen in Group 1, even though there was reduced BMD at the L1-
L2 specific site. The third group that supplemented with Ca/D and the collagen 
boosting B6 decreased further bone loss at all sites. BALP was significantly 
decreased in both osteopenic groups, indicating less bone remodeling was 
occurring [18]. 
 A study as recent as 2010 investigated vitamin D status as it correlated to 
BMD in African American women. Forty-four subjects were recruited from a 
community health center and considered to be of low socio-economic status. 
Data for BMD and serum 25(OH) D was collected from clinic records. Subjects 
were given tablets containing 1000 mg of calcium, along with 400 IU of vitamin D. 
and instructed to take one tablet daily without making any dietary or sun 
exposure changes throughout the duration of the 6-week study. Researchers 
found significant correlation between BMD and 25 (OH) D levels in these 
subjects, however, even with supplementation and springtime sun exposure, 
Vitamin D serum levels were not increased during the duration of this six week 
study [32]. 
VITAMIN D and MUSCLE 
Vitamin D receptors are also located within skeletal muscle; therefore a 
deficiency of the vitamin may affect muscular strength and function. In fact, 
according to Ceglia, 2009, type II muscle fibers are primarily affected in adults 
who are deficient in Vitamin D. These type II fibers are the first muscle fibers to 
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be recruited when a person is attempting to react to a fall to catch oneself [8]. 
Another study used 48 elderly persons who had previously survived a stroke. 
The subjects were given Vitamin D2 supplements in a dosage of 1000 IU per 
day. Muscle biopsies over a two year period demonstrated that not only did the 
percentage of type II muscle fibers increase, but also the diameter of the muscle 
fibers themselves [25]. 
  Previous research shows that older individuals with higher serum levels of 
Vitamin D showed better muscle performance in their lower extremities than did 
those individuals with lower serum levels of Vitamin D [15]. In this study, over 
1300 subjects from the ongoing LASA (Longitudinal Aging Study Amsterdam) 
participated. The physical tests for subjects included a three-meter walk test, in 
which the time it took a participant to walk three meters, turn and walk back to 
the starting point was measured. Subjects also performed another timed test, 
during which they were to rise from a chair, and sit back down five times with 
their arms folded across their chest. Finally subjects perform what investigators 
called a “tandem stand” in which subjects were to stand with one foot directly 
behind the other in a perfectly straight line and instructed to hold the position for 
at least 10 seconds. Tests were scored on a 1-4 point system. The subject 
groups with lower levels of serum Vitamin D scored significantly lower on these 




Other studies showed that those older individuals with reduced levels of 
serum Vitamin D were at an increased risk for repeated falls [31], also using 
subjects from the LASA study. Falls were self-reported on a fall calendar every 
three months. Groups were separated into those who experienced one fall, 
repeated falls, or zero falls. The individuals who fell repeated times in this 
investigation demonstrated a higher prevalence of Vitamin D deficiency, and this 
risk increased particularly when the levels of serum 25 OH D were less than 10 
ng/ml. Repeated falls may occur due to a lack of muscular strength, function and 
coordination, as well as reaction time. Abou-Raya, et al found not only did 
patients with PD and lower levels of Vitamin D suffer more falls, they suffered 
more skeletal fractures [1]. Furthermore, intervention studies for neurologically 
normal older adults (NNOA) show that treatment with D3 and calcium over a 
three month time period resulted in a 49% reduction in the risk of falling, when 
compared to calcium supplementation alone [4].  
As previously stated, research shows that vitamin D supplementation is 
beneficial for muscular performance in NNOA, however, more research is 
needed to determine the effect of Vitamin D supplementation on bone health 
combined with strength and function in persons with PD. 
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